How a struggling biotech company became a university ‘spin-in’

by | Sep 10, 2024 | Uncategorized | 0 comments

Nature, Published online: 10 September 2024; doi:10.1038/d41586-024-02627-8

Despite meeting a clinical and societal need for snakebite antivenom development, VenomAb folded after four years, propelling co-founder Andreas Laustsen-Kiel to a role that combines entrepreneurship and academia.

Archive Posts

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.